Pneumocystis jirovecii Pneumonia in Patients with Nephrotic Syndrome: Application of Lymphocyte Subset Analysis in Predicting Clinical Outcomes

Table 1

Patient characteristics and managements.

Variables	N = 57
Age (years)	48.1 ± 16.9
Sex (female)	29 (50.9%)
Duration of nephrotic syndrome (months)	23.7 ± 37.5
Ever-smokers	10 (17.5%)
Comorbidity
Chronic respiratory disease	1 (1.8%)
Hypertension	30 (52.6%)
Diabetes mellitus	13 (22.8%)
Type 2 diabetes	4 (7.0%)
Steroid-induced diabetes	9 (15.8%)
Heart disease	7 (12.3%)
Coronary heart disease	4 (7.0%)
Arrhythmia	1 (1.8%)
Hypertensive heart disease	1 (1.8%)
Hypothyroid heart disease	1 (1.8%)
Use of immunosuppressants
Long-term corticosteroids	56 (98.2%)
Duration of corticotherapy (months)	12.6 ± 18.1
Other immunosuppressive agents	50 (87.7%)
Diagnosis of PCP
PCR	56 (98.2%)
GMS	8 (14.0%)
Managements
ICU admission	37 (64.9%)
Mechanical ventilation	30 (52.6%)
CRRT	9 (15.8%)
ECMO	1 (1.8%)

PCP: Pneumocystis jirovecii pneumonia, PCR: polymerase chain reaction, GMS: Grocott’s methenamine silver stain, ICU: intensive care unit, CRRT: continuous renal replacement therapy, and ECMO: extracorporeal membrane oxygenation. Data were presented as mean ± SD or numbers (%).